# Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)

> **NCT02231918** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 26 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** MIRAPEX® - low
- **DRUG:** MIRAPEX® - medium
- **DRUG:** MIRAPEX® - high

## Key facts

- **NCT ID:** NCT02231918
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231918, "Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02231918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*